# Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer

> **NCT02558868** · PHASE2 · COMPLETED · sponsor: **Zhejiang University** · enrollment: 80 (actual)

## Conditions studied

- Pancreatic Neoplasms

## Interventions

- **DRUG:** Irinotecan
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT02558868
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-01
- **Primary completion:** 2017-09-30
- **Final completion:** 2017-12-31
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2018-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02558868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02558868, "Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02558868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*